Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: May 5, 2008
Last updated: April 15, 2016
Last verified: April 2016
The safety, tolerability, efficacy and pharmacokinetics of ASA404 when administered in combination with paclitaxel and Carboplatin are assessed. ASA404 is administered intravenously every 21 days to Japanese patients with Non small cell lung cancer.

Condition Intervention Phase
Non-small Cell Lung Cancer
Drug: ASA404
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With NSCLC

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To assess the safety profile and tolerability of ASA404 when administered in combination with paclitaxel and carboplatin in Japanese patients with non small cell lung cancer [ Time Frame: First cycle ]

Secondary Outcome Measures:
  • To characterize the pharmacokinetics profile of ASA404 in Japanese patients [ Time Frame: every 2 cycles ]

Enrollment: 15
Study Start Date: April 2008
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ASA404 Drug: ASA404


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Histologically or cytologically confirmed non-small cell carcinoma of the lung.
  2. Newly diagnosed Stage IIIb disease or Stage IV disease
  3. No prior treatment for Stage IIIb/IV non-small cell carcinoma of the lung (Note: Prior neoadjuvant or adjuvant chemotherapy within 6 months is allowed.)
  4. Age ≥ 20 years old
  5. WHO Performance status of 0-1
  6. Lab values within the range as defined below within 2 weeks of study registration (Note: without the use of growth factors or blood transfusions):

    • Absolute neutrophil count (ANC) > 2.0 x 109/L
    • Platelets ≥ 100 x109/L
    • Hemoglobin ≥ 9.5 g/dL
    • Serum creatinine ≤ 1.5 x ULN or 1.5 mg/dL
    • Serum bilirubin ≤ 1.5 x ULN
    • Aspartate transaminase (AST) and alanine transaminase (ALT)

      ≤ 2.5 x ULN

    • PT-INR ≤ 1.5 x ULN
    • Potassium ≥ LLN or correctable with supplements.
    • Total calcium (corrected for serum albumin) ≥ LLN or correctable with supplements.
    • Magnesium ≥ LLN or correctable with supplements.
    • Females of child-bearing potential must have negative pregnancy test (serum)
  7. Life expectancy ≥ 12 weeks
  8. Written informed consent obtained according to local guidelines

Exclusion criteria:

  1. Patients having symptomatic CNS metastases and requiring treatment
  2. Patients with second primary cancer, with the exception of non-melanoma skin cancer or cervical cancer in situ.
  3. Radiotherapy ≤ 4 weeks prior to registration (In case of palliative radiotherapy 2 weeks prior to registration
  4. Major surgery ≤ 4 weeks prior to registration (major surgery is defined by the use of general anesthesia). Minor surgery ≤ 2 weeks prior to registration. Insertion of a vascular access device is allowed. Patients must have recovered from all surgery-related complications.
  5. Concurrent use of other investigational agents and patients who have received investigational agents ≤ 4 weeks prior to registration
  6. Prior exposure to VDAs or other vascular targeting agents (anti-VEGF, anti-VEGF receptor agents, anti-EGFR agents
  7. Patients with pleural effusion to be drained (Patients who have recurrence of pleural effusion and/or it takes 2 weeks before registration after drainage are allowed)
  8. Patients with recent hemoptysis associated with NSCLC (>1 teaspoon in a single episode within 4 weeks)
  9. Known allergy or hypersensitivity to platinum-containing drugs, taxanes, other drugs formulated in Cremophor EL (polyoxyethylated castor oil) or any known excipients of these drugs.
  10. Peripheral sensory neuropathy with functional impairment (CTC Grade 2 neuropathy, regardless of causality)
  11. ≥ CTC Grade 2 cardiac arrhythmias (i.e. symptomatic, but may not require medications).
  12. Pregnant or breast feeding females
  13. Patients who take medicine that are known to prolong the QT interval
  14. Women of child bearing potential or sexually active males, unwilling or unable to use the required highly effective method(s) of contraception for both sexes while receiving treatment and for at least 6 months after the discontinuation of study treatment. (Adequate forms of contraception include IUD, oral or depot contraceptive or the barrier method plus spermicide.)
  15. Patients with any one of the following

    • Patients with Long QT Syndrome
    • Patients with a Baseline 12-lead ECG QTc of > 450 msec in males or > 470 msec in females.
    • Congestive heart failure(NY Heart Association class III or IV)
    • Patients with a myocardial infarction within 12 months of study entry
    • Unstable or poorly controlled angina pectoris
    • History of poorly controlled hypertension with anti-hypertensive regimen
    • History of a sustained ventricular tachycardia
    • Any history of ventricular fibrillation or Torsades de Pointes
    • Right bundle branch block and left anterior hemiblock (bifasicular block)
    • Bradycardia defined as heart rate < 50 beat per minutes
  16. Concurrent severe and/or uncontrolled medical disease (i.e. uncontrolled diabetes, chronic renal disease, chronic liver disease, confirmed diagnosis of HIV infection or active uncontrolled infection).
  17. Patients known to be HBV or HCV positive
  18. Significant neurological or psychiatric disorder which could compromise participation in the study
  19. Patient unwilling or unable to comply with the protocol
  20. Patients who are not adequate to enter the study decided by the investigator from the medical point of view.

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00674102

Novartis Investigative Site
Aichi, Japan
Novartis Investigative Site
Osaka, Japan
Novartis Investigative Site
Shizuoka, Japan
Novartis Investigative Site
Tokyo, Japan
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT00674102     History of Changes
Other Study ID Numbers: CASA404A1101
Study First Received: May 5, 2008
Last Updated: April 15, 2016

Keywords provided by Novartis:
Vascular disrupting agent
Non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on April 25, 2017